¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"thyroid carcinoma risk factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • comedo carcinoma
    ¸éÆ÷¾ÏÁ¾, ¿©µå¸§Áý¸ð¾ç¾ÏÁ¾
  • carcinoma
    ¾ÏÁ¾
  • carcinoma in situ
    Á¦ÀÚ¸®¾ÏÁ¾
  • corpus carcinoma
    ÀڱøöÅë¾ÏÁ¾, ÀÚ±ÃüºÎ¾ÏÁ¾
  • duct carcinoma
    °ü¾ÏÁ¾
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
  • eccrine carcinoma
    ¿¡Å©¸°¾ÏÁ¾
  • embryonal carcinoma
    ¹è¾Æ¾ÏÁ¾
  • epidermoid carcinoma
    Ç¥ÇǸð¾ç¾ÏÁ¾
  • follicular carcinoma
    °©»ó»ù¼ÒÆ÷¾ÏÁ¾, ¼ÒÆ÷¾ÏÁ¾
  • giant cell carcinoma
    °Å´ë¼¼Æ÷¾ÏÁ¾
  • glandular carcinoma
    »ù¾ÏÁ¾, ¼±¾ÏÁ¾
  • granulosa cell carcinoma
    °ú¸³¼¼Æ÷¾ÏÁ¾
  • hepatocellular carcinoma
    °£¼¼Æ÷¾ÏÁ¾
  • invasive carcinoma
    ħ½À¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • risk
    À§Çè, À§Çèµµ
  • radiation risk
    ¹æ»ç¼±À§Çèµµ
  • recurrence risk
    Àç¹ßÀ§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ
  • risk ratio
    À§Çèµµºñ
  • risk benefit ratio
    À§ÇèÆíÀͺñ
  • surgical risk
    ¼ö¼úÀ§Çèµµ
  • acinar carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • adenocystic carcinoma
    (¢¡adenoid cystic carcinoma) »ù³¶¾ÏÁ¾
  • adenoid cystic carcinoma
    »ù³¶¾ÏÁ¾
  • adenoma-carcinoma sequence
    »ùÁ¾¾ÏÁ¾¼ø¼­
  • adnexal carcinoma
    ºÎ¼Ó±â°ü¾ÏÁ¾
  • apocrine gland carcinoma
    ¾ÆÆ÷Å©¸°¶¡»ù¾ÏÁ¾
  • arsenical carcinoma
    ºñ¼Ò¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arsenical carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ¾Ï(Á¾)
  • gastric carcinoma
    À§¾ÏÁ¾(êÖäßðþ)
  • giant cell carcinoma
    °Å¼¼Æ÷¾ÏÁ¾
  • glandular carcinoma
    ¼±¾ÏÁ¾(¼±¾ÏÁ¾).
  • glassy cell carcinoma of cervix
    À¯¸®¾ç ¼¼Æ÷ ÀڱðæºÎ¾Ï
  • granular basal cell carcinoma
    °ú¸³ ±âÀú¼¼Æ÷¾Ï
  • granulosa cell carcinoma
    (³­¼Ò)°ú¸³¸·¼¼Æ÷ ¾ÏÁ¾(Õ°áµÎ¨í£Ø¯á¬øà ðþ).
  • hepatocellular carcinoma
    °£¼¼Æ÷¼º ¾Ï
  • hepatocellular carcinoma
    °£¼¼Æ÷¾ÏÁ¾(ÊÜá¬øàäßðþ)
  • pigmented basal cell carcinoma
    »ö¼ÒÄ§Âø ±âÀú¼¼Æ÷¾Ï
  • pilomatrix carcinoma
    ¸ð¹ß±âÁú ¾Ï(Á¾)
  • postcricoid carcinoma
    ÈÄÀ±(»ó)¾ÏÁ¾
  • primary bronchogenic carcinoma
    ¿ø¹ß(¼º)±â°üÁö¾Ï
  • primary carcinoma
    ¿ø¹ß¾ÏÁ¾(ê«Û¡äßðþ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cold thyroid nodule
    °©»ó¼±³Ã°áÀý.
  • cricothyroid branch of superior thyroid artery
    À§°©»ó»ùµ¿¸ÆÀÇ À±»ó°©»ó°¡ Áö, »ó°©»ó¼±µ¿¸ÆÀÇ À±»ó°©»óÁö.
  • cricothyroid branch of superior thyroid artery
    »ó°©»óµ¿¸ÆÀÇ À±»ó°©»ó°¡Áö{ÇØ}
  • esophageal branches of inferior thyroid art ery ; rami esophagei artery thyroideae in fe r io ris
    ¾Æ·¡°©»ó¼±µ¿¸ÆÀÇ ½Äµµ°¡Áö, Çϰ©»ó¼±µ¿¸ÆÀÇ ½ÄµµÁö.
  • functioning thyroid nodule
    ±â´É¼º °©»ó¼±°áÀý.
  • gland, isthmus of thyroid
    °©»ó¼± ÇùºÎ
  • human thyroid stimulating hormone =HTSH
    »ç¶÷°©»ó¼±ÀÚ±ØÈ£¸£¸ó.
  • human thyroid stimulating hormone =HTSH
    °©»ó¼±ÀÚ±ØÈ£¸£¸ó.
  • inferior thyroid artery
    ¾Æ·¡°©»óµ¿¸Æ
  • inferior thyroid artery <³ª> arteria thyr(e)oidea inferior
    Çϰ©»ó¼±µ¿¸Æ(Çϰ©»ó¼±µ¿¸Æ).
  • inferior thyroid artery ³ª arteria thyr(e)oidea inferior
    ¾Æ·¡°©»ó»ù µ¿¸Æ, Çϰ©»ó¼±µ¿¸Æ(ù»Ë£ßÒàÍÔÑØæ).
  • inferior thyroid tubercle
    Çϰ©»ó°áÀý
  • inferior thyroid veins
    ¾Æ·¡°©»óÁ¤¸Æ
  • intrathoracic thyroid
    Èä°­³»°©»ó¼±.
  • isthmus of thyroid gland
    °©»ó¼±(°©»ó¼±)ÇùºÎ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
MCT manual cervical traction; mean cell thickness; mean cell threshold; mean circulation time; mean corp...
MTC mass transfer coefficient; maximum tolerated concentration; maximum toxic concentration; medical tes...
PACT papillary carcinoma of thyroid; precordial acceleration tracing; prepaid accountable care term
PTC papillary thyroid carcinoma; percutaneous transhepatic cholangiography; phase transfer catalyst; phe...
TPC thromboplastic plasma component; thyroid papillary carcinoma; total patient care; total plasma catec...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
GEF Guanine nucleotide Exchange Factors
HGF Hemopoietic growth factors
HBGF Heparin binding growth factors
IGFBPs Insulin-like growth factors and their binding proteins
IGF-II Insulin-like growth factors I and II
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bladder carcinoma
    ¹æ±¤ ¾ÏÁ¾
  • brochioloalveolar carcinoma
    ¼¼±â°üÁö ÆóÆ÷ ¾ÏÁ¾
  • bronchiolar carcinoma
    ¼¼±â°üÁö¼º ¾Ï, ¼¼±â°üÁö¼º ¾ÏÁ¾
  • bronchogenic carcinoma
    ±â°üÁö ¾Ï
    ±â°üÁö¿¡ »ý±ä ¾Ï. Á¶Á÷ÇÐÀûÀ¸·Î´Â ¼± ¾Ï, ÆíÆò»óÇÇ ¾Ï, ¹ÌºÐÈ­ ¾Ï µîÀ¸·Î ºÐ·ùÇÑ´Ù. »ê¾÷ÀÇ ¹ß´Þ¿¡ ¼ö¹ÝµÈ ´ë±â ¿À¿° ¹× Èí¿¬ µîÀ¸·Î ÀÎÇØ ±Ù·¡¿¡ ÀÌ ÀÓÁ¾ÀÇ ¹ß»ý ºóµµ°¡ ±Þ°ÝÈ÷ »ó½ÂÇϰí ÀÖ´Ù.
  • carcinoma adenomatosum
    ¼± ¾ÏÁ¾
    ¼± Á¶Á÷¿¡¼­ »ý±â´Â ¾Ï. ¶Ç´Â ¼± Á¶Á÷À¸·Î ÀÎ½ÄµÉ ¼ö ÀÖ´Â ±¸Á¶ÀÇ ¼¼Æ÷·Î Çü¼ºµÇ´Â ¾Ï. ¼±¾ÏÀº ÁÖ¿äÇÑ ¼¼Æ÷ ¹è¿­ÀÇ Çü¿¡ ÀÇÇÏ¿© À¯µÎ»ó, Æ÷»ó µîÀ¸·Î ºÐ·ùµÈ´Ù. ¶Ç´Â ¼¼Æ÷ÀÇ Æ¯¼öÇÑ »ý¼º¹°¿¡ ÀÇÇÏ¿© Á¡¾×¼º ¼±¾Ï µîÀ¸·Î ºÐ·ùµÈ´Ù.
  • carcinoma erysipelatodes
    ´Üµ¶¾ç ¾ÏÁ¾
  • carcinoma in situ
    »óÇdz» ¾ÏÁ¾, µ¿¼Ò³» ¾ÏÁ¾, ÀνÃÅõ ¾ÏÁ¾
    ÇÇºÎ¿Í Á¡¸·À» ÀÌȯÇÏ´Â Çü¼º Àå¾Ö¼º »óÇÇ ÁúȯÀ¸·Î¼­ Àü¾Ï º´¼Ò·Î »ý°¢µÇ°í ÀÖ´Ù. °¢È­ ÀÌ»óÁõÀÌ ½ÉÇÏÁö¸¸ ħ¹üÀº µÇÁö ¾ÊÀº »óÅÂÀÌ´Ù.
  • carcinoma ossificans
    È­°ñ¼º ¾ÏÁ¾
    °£Áú¿¡ À¯°ñ, °ñ È­»ýÀÌ ÀϾ´Â ¾ÏÁ¾.
  • carcinoma portionis
    Àڱà ÁúºÎ ¾ÏÁ¾
  • carcinoma telangiectaticum
    ¸ð¼¼Ç÷°ü È®À强 ¾Ï, ¸ð¼¼Ç÷°ü È®À强 ¾ÏÁ¾
  • central mucoepidermoid carcinoma
    °ñ³» Á¡¾× Ç¥ÇǾÏ
    »ó, ÇϾǿ¡ Áß½ÉÀûÀ¸·Î ¹ß»ýÇϸç, ¹è¹ß»ý±â¿¡ Ÿ¾×¼± ¼¼Æ÷°¡ À¯ÀԵǾú°Å³ª Ä¡¼º ³¶ÀÇ Á¡¾× ¼¼Æ÷°¡ Á¾¾çÀ¸·Î ÀüȯµÇ¾î »ý±æ ¼ö ÀÖ´Ù.
  • cheek carcinoma
    ÇùºÎ ¾Ï
  • clear cell basal cell carcinoma
    Åõ¸í ¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • colloid carcinoma
    ÄÝ·ÎÀ̵强 ¾ÏÁ¾
  • colorectal carcinoma
    °áÀå Á÷Àå¾Ï
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
growth factors Proteins involved in cell differentiation and growth.Growth factors are essential to the normal cell cycle, and are thus vital elements in the life of animals from conception to death. Among other things, they mediate foetal development, play a role in maintenance and repair of tissues, stimulate production of blood cells, and, gone awry, participate in cancerous processes.
(05 Mar 2000)
meteorological factors The atmospheric phenomena which pertain to climate and weather.
(12 Dec 1998)
clearing factors Lipoprotein lipases that appear in plasma during lipaemia and catalyze hydrolysis of triglycerides only when the latter are bound to protein and when an acceptor (e.g., serum albumin) is present, thus "clearing" the plasma.
(05 Mar 2000)
colicin factors Plasmids determining the potentiality of a bacterium to produce colicins. They are cytoplasmic elements whose integration into the bacterial chromosome has not been demonstrated except for the col b and col v factors.
(12 Dec 1998)
colonisation factors <microbiology> The pili on enteropathogenic forms of E. Coli facilitate adhesion of the bacteria to receptors (probably GM1 gangliosides) on gut epithelial cells and are often referred to as colonisation or adherence factors.
Colonisation factor antigens may be plasmid coded, are essential for pathogenicity and are strain specific, for example K88 diarrhoea in piglets), CFAI and CFAII on strains causing similar disease in man.
(18 Nov 1997)
cord factors Trehalose-6,6'-dimycolate. A toxic glycolipid of mycobacterium tuberculosis. Induces cellular biochemical disfunction in animals; used as immunoadjuvant.
(12 Dec 1998)
myogenic regulatory factors A family of muscle-specific transcription factors which bind to DNA in control regions and thus regulate myogenesis. All members of this family contain a conserved helix-loop-helix motif which is homologous to the myc family proteins. These factors are only found in skeletal muscle. Members include the myod protein (myod protein), myogenin, myf-5, and myf-6 (also called mrf4 or herculin).
(12 Dec 1998)
coupling factors Proteins that restore phosphorylating ability to mitochondria that have lost it, i.e., have become "uncoupled" so that oxidation and electron transport no longer produces ATP. Usually termed coupling factor F1, F2, etc.
Synonym: C factors.
(05 Mar 2000)
haematopoietic cell growth factors These growth factors comprise a family of haematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. Erythropoietin and the colony-stimulating factors belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.
(12 Dec 1998)
haemolysin factors Plasmids controlling the synthesis of haemolysin by bacteria.
(12 Dec 1998)
precipitating factors Factors associated with the definitive onset of a disease, illness, accident, behavioural response, or course of action. Usually one factor is more important or more obviously recognizable than others, if several are involved, and one may often be regarded as "necessary". Examples include exposure to specific disease; amount or level of an infectious organism, drug, or noxious agent, etc.
(12 Dec 1998)
predisposing factors Attitudinal, personality, and related factors that motivate and guide an individual to take certain health actions.
(05 Mar 2000)
sex factors Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from sex characteristics, anatomical or physiological manifestations of sex, and from sex distribution, the number of males and females in given circumstances.
(12 Dec 1998)
socioeconomic factors Social and economic factors that characterise the individual or group within the social structure.
(12 Dec 1998)
steam conversion factors (approximations) 1 pound of steam = 1,000 Btu = .3 kW. 10,000 lbs/hr steam = 300 boiler horsepower.
(05 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á